BioSpace News Archive

According to the report, the global X-ray detectors market was valued at US$ 2.5 Bn in 2020 and is projected to expand at a moderate CAGR from 2021 to 2031.

The vendor landscape of the global reprocessed medical devices market is significantly consolidated with the leading few companies collectively accounting for a lion’s share in the overall market, observes Transparency Market Research in a recent report.

The global Methicillin-resistant Staphylococcus Aureus Drugs Market was valued at approximately US$ 2.9 Bn in 2016 is projected to register cumulative annual growth rate of over 3.2% from 2017 to 2025, according to a new report published by Transparency Market Research titled “Methicillin-resistant Staphylococcus Aureus Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.

The rise in world population, coupled with the increasing number of various chronic and acute diseases are the prime factors augmenting the health information exchange market.

Current and ongoing clinical trials in oncology have shed light on multifactorial pathogenicity of the syndrome cancer cachexia.

The rivalry between Sun Pharmaceuticals Ltd., Valeant Pharmaceuticals International Inc., Mylan N.V., F. Hoffmann-La Roche Ltd., and Merck & Co. Inc. characterizes the competitive landscape present in the global basal cell carcinoma treatment market, states a new research study by Transparency Market Research.

The global animal blood plasma products and derivatives market is has a fragmented vendor landscape due to the presence of several players, Transparency Market Research observes.

OSE Immunotherapeutics SA presented the first positive preclinical efficacy data on its novel myeloid cell immune checkpoint target, CLEC-1, at the Society for Immunotherapy of Cancer 36th Annual Meeting in Washington D.C. held in-person and virtually on November 10 – 14, 2021.

BioArctic AB and partner Eisai held several oral presentations at the 14th Clinical Trials on Alzheimer’s Disease conference, November 9-12, 2021, revealing new data on lecanemab, an investigational anti-amyloid beta protofibril antibody.

Hansa Biopharma AB, “Hansa”, announces its decision to initiate a pivotal Phase 3 clinical study of imlifidase to treat anti-GBM disease, following a successful pre-IND meeting with the U.S. Food and Drug Administration.